| Literature DB >> 35854641 |
Kahlilia C Morris-Blanco1, Anil K Chokkalla1, Vijay Arruri1, Soomin Jeong1,2, Samantha M Probelsky1, Raghu Vemuganti1,2,3.
Abstract
Accumulating evidence indicates a central role for epigenetic modifications in the progression of stroke pathology. These epigenetic mechanisms are involved in complex and dynamic processes that modulate post-stroke gene expression, cellular injury response, motor function, and cognitive ability. Despite decades of research, stroke continues to be classified as a leading cause of death and disability worldwide with limited clinical interventions. Thus, technological advances in the field of epigenetics may provide innovative targets to develop new stroke therapies. This review presents the evidence on the impact of epigenomic readers, writers, and erasers in both ischemic and hemorrhagic stroke pathophysiology. We specifically explore the role of DNA methylation, DNA hydroxymethylation, histone modifications, and epigenomic regulation by long non-coding RNAs in modulating gene expression and functional outcome after stroke. Furthermore, we highlight promising pharmacological approaches and biomarkers in relation to epigenetics for translational therapeutic applications.Entities:
Keywords: Biomarkers; cerebral ischemia; epigenomics; hemorrhagic stroke; neuroprotection
Mesh:
Substances:
Year: 2022 PMID: 35854641 PMCID: PMC9580166 DOI: 10.1177/0271678X221116192
Source DB: PubMed Journal: J Cereb Blood Flow Metab ISSN: 0271-678X Impact factor: 6.960